skip to primary navigationskip to content

CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial Drugs

When Sep 06, 2019
from 08:15 AM to 06:00 PM
Where Christ's College Cambridge
Contact Name
Contact Phone +44 (0) 1223 330 047
Add event to calendar vCal

CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial Drugs

A profound market failure around the production of new antibiotics is seriously hampering our collective ability to protect people from the dire consequences of Antimicrobial Resistance. Antimicrobial resistance (AMR) continues to expand, raising the risk of a future public health crisis. Numerous conferences have been organized to address the scientific challenges of AMR, such as the need to engineer novel antibiotics. However, science in isolation will not suffice. 

This symposium explores the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem will help design a better legal toolkit to promote antimicrobial innovation and limit the impact of resistance on global health.

The CeBIL Symposium is organized by the Cambridge Centre for Law, Medicine and Life Sciences, the Center for Advanced Studies in Biomedical Innovation Law at the University of Copenhagen, and the CeBIL International Collaboration including partners; such as CARB-X, Boston University SIDR, and PORTAL at Harvard Medical School. The Symposium is generously supported by the Novo Nordisk Foundation, the Cambridge Academy for Therapeutic Sciences (CATS), and the Cambridge Infectious Disease Interdisciplinary Research Centre.

Held at the University of Cambridge, an international hub for legal and scientific expertise, we hope the event will mobilize legal, economic, business, medical and scientific experts – early, mid, and late career – who recognize the need to work together to avert the AMR crisis.


Draft Programme

8.35am- 18.00 Symposium

18.00-19.00 Drinks Reception


8.45 Welcome and objectives
Timo Minssen (LML Copenhagen )  & Kathy Liddell (CeBIL Cambridge)

9.00 Legal approaches for conserving and producing new
antimicrobials: an overview

Aaron Kesselheim (PORTAL Harvard) & Kevin Outterson (CARB-X)

9.30 Open Discussion, first comment: Gordon
Dougan Cambridge scientist, SME entrepreneur ‘Microbiotica’

Session 2 Framework Sector 2 -- PROPERTY BASED INITIATIVES

9.50 Part 1: Which property-based incentives for antimicrobial
production work best?: Empirical evidence on patents (for different sectors), market authorisation,  vouchers and QIDP designation/GAIN Act

Jonathan Darrow (PORTAL Harvard) & Sven Bostyn (CeBILCopenhagen)

10.10 Open discussion,  first comment: TBC

10.25 Part 2: Further evidence on the property-based incentives that
work best for antimicrobial production?

Michael Sinha (PORTAL, Harvard )& Dagim Belay (CeBIL, Copenhagen)

10.45 Open discussion, first comment: David McIntosh MSD/Imperial College London


Session 3 Framework Sector 4 -- REGULATION BASED INITIATIVES

11.30 Does expedited review as an incentive for antimicrobial
production have net benefits? Empirical evidence

Aaron Kesselheim (PORTAL Harvard)

11.50 Open Discussion, first comment: Nicholas
Brown Medical Microbiologist, Cambridge

12.05 Centrally co-ordinated (regulation-based) ideas from other
industries to re-stock the pool of antibiotics

Christine Årdal (Norwegian Institute for Public Health DRIVE-AB)

12.25 Open discussion, first comment:
Lloyd Payne Evotec

12.45 What role can international law play in regulating the global
antimicrobial commons?

Steven Hoffman (York University, Canada)

1.05 Open discussion, first comment:
Peter Beyer Innovation Division, WHO



2.15 Vision for a global research effort in AMR based on the model of
the Intergovernmental Panel on Climate Change

Professor Dame Sally Davies
Chief Medical Officer

2.45 Open discussion,
first comment: Tim Jinks Drug resistant infections, Wellcome Trust

Session 5 Framework Sector 6 -- CONTRACT BASED INITIATIVES

3.05 What are delinked market entry rewards, and are they working to
stimulate antibiotic production whilst conserving use? Empirical evidence.

James Anderson UK Pilot project, (Public Policy) GSK

3.25 Open discussion, first comment: TBC

3.40 What is an appropriate way to value antibiotics for value-based

Colm Leonard (NICE UK)

4.00 Open discussion, first  comment: Flavio Toxværd Cambridge



4.45 Human Rights perspective TBC

4.50 International perspective TBC

4.55 R&D perspective  TBC

5.00 Investment perspective  Aleks Engel REPAIR, Denmark

5.05 Science perspective  Sharon Peacock Clinical Microbiology, Cambridge

5.10 R&D perspective Jean-Pierre Pacaud GARDP

5.15 Audience discussion



 More Information:























Timo Minssen & Kathy Liddell
Copenhagen Cambridge


What we do

Navy Blue Logo CID PNG

Cambridge Infectious Diseases is an Interdisciplinary Research Centre at the University of Cambridge. We promote an interdisciplinary approach to addressing the challenge of reducing the burden of infectious diseases globally. Our virtual network crosses all six schools of the University and sector leading institutes across Cambridge. Read more


Follow us @CamInfectDis

RSS Feed Latest news

University Enterprise Zone aims to drive innovation across Cambridge

Sep 20, 2019

Cambridge is to establish a University Enterprise Zone as part of a new government initiative announced today by Universities Minister Chris Skidmore.

Investigating the zoonotic disease risk of displaced communities- 21 August 2019

Aug 21, 2019

Dorien Braam's PhD investigates whether displacement puts communities at greater risk of zoonotic disease transmission.

View all news

Annual Meeting of Minds 2019 - Register now!

Spanish Flu: Cambridge scientists discuss the historic warning to us all.